Key Highlights
- Shares added around 2.1% in the session, extending a gain of well over 100% over the past year
- Full-year 2025 Revenue rose 140% to $11.7m, with the company posting a maiden profit before tax of about $0.3m
- Cash stood at only about $0.9m at the 2025 year-end, with $450,000 drawn on a $500,000 Credit facility
- Nigeria was the largest market in 2025 at about $6.6m, ahead of the United States at $2.7m
- A third Gulf of Mexico produced-water Lease with an unnamed super-major is expected to contribute roughly $850,000 to 2026 revenue
A tiny AIM-listed water-treatment specialist that has quietly re-rated into profit, MyCelx has become one of the London junior market's more intriguing environmental-technology stories. The latest uptick keeps a stock that has already multiplied in value firmly on speculative screens.
A micro-cap water play edges higher
Shares in MyCelx Technologies (LSE:MYX) added around 2.1% in the session, a modest gain that extends a remarkable twelve months for a company that spent years as an overlooked AIM minnow. The Norcross, Georgia-based group develops filtration technology that strips oil and other Hydrocarbons from water, sitting at the intersection of two themes that periodically excite small-cap investors: the oil-and-gas services cycle and the broader clean-water opportunity.
There was no single company announcement on the day that obviously accounts for the move. MyCelx's most recent disclosures were a trading update, a holdings notification the following day, and a notice of its 2026 annual meeting. Against that backdrop, the latest price action looks more like a continuation of the re-rating that has gripped the stock since the turn of the year than a response to fresh news. The move comes as investors reassess a Business that has swung from persistent losses into profitability.
The context matters because MyCelx is genuinely small and thinly traded. With roughly six employees and a Market Capitalisation of only around £16m, even modest buying can move the price sharply. The shares have run from a 52-week low near 20p to the high-60s in pence, a gain of well over 100% in a year, leaving them sensitive to any disappointment on execution.
From chronic losses to a maiden profit
The foundation of the re-rating is a genuine turnaround in the numbers. In final results for the year to 31 December 2025, MyCelx reported revenue of $11.7m, up 140% from $4.9m. Gross Profit jumped to $5.6m from $1.3m, lifting gross Margin to 48% from 27%, while EBITDA turned positive at roughly $0.7m against a $2.2m loss. Profit before tax came in at about $0.3m, a swing from a $2.6m loss and the company's first move into the black after years of red ink.
That outcome was flagged in a January trading update that beat cautious market expectations; analysts had been braced for losses, so a profit marked what management called an important inflection point, and the shares jumped more than 20% in a single session. The figures did carry caveats: revenue landed a little below the roughly $12.5m the market had pencilled in, and reported EBITDA included a modest gain from the earlier disposal of the Saudi Arabian operations.
Cash remains the tightest part of the story. MyCelx ended 2025 with only about $0.9m of cash and equivalents, down from $1.3m, and had drawn roughly $450,000 of a $500,000 credit Facility arranged in August 2025. Management pointed to expected first-quarter collections of around $4m to ease the position, but the Balance Sheet leaves little margin for error and keeps funding central to the Investment case.
The revenue mix is also revealing. Nigeria was comfortably the largest market in 2025 at about $6.6m, ahead of the United States at $2.7m and the Middle East at $1.4m. That concentration means reported growth can hinge heavily on the timing of a small number of large contracts.
Contracts and a shift toward recurring revenue
Underpinning the improved trading is a refreshed strategy focused on three markets: produced-water treatment for oil and gas, PFAS remediation, and industrial water services. Management has been explicit about moving away from lumpy one-off equipment sales toward higher-quality, recurring income from equipment leases and sales of MyCelx's proprietary filtration media.
Recent awards fit that template. During 2025 the company secured a $3.9m produced-water treatment project in the US Permian Basin and won a mobile PFAS rental contract for a US Department of Defense site in North Dakota. It has also built an offshore presence, announcing in May 2026 its third Gulf of Mexico produced-water contract with an unnamed super-major — an equipment lease expected to contribute roughly $850,000 to 2026 revenue and about $1.5m annualised.
MyCelx frames the produced-water opportunity around a structural shift in oil and gas toward recycling and reuse rather than disposal. It has highlighted that in the Permian Basin water-to-oil ratios already exceed five barrels of water for every barrel of oil produced, a figure it expects to keep rising as it expands the addressable market for treatment technology.
What could drive the shares next?
The clearest potential catalysts are further contract wins, particularly repeat or expanded work in the Permian Basin and Gulf of Mexico, where the recurring-lease model could build a more predictable revenue base. Evidence that coming interim results confirm continued momentum would help validate the re-rating, as would progress converting the much-discussed PFAS opportunity into signed, revenue-generating contracts.
Sentiment toward oil-and-gas capital spending is another swing factor. As a supplier tied to drilling and production, MyCelx tends to benefit when operators invest, so a supportive backdrop for US spending could feed through to demand. Investors will also watch the balance sheet: any move to strengthen cash could remove an overhang, though it may equally raise the prospect of dilution.
Risks investors should watch
The risks are considerable and specific. The thin cash position and reliance on a small credit line mean MyCelx has limited financial headroom, and any delay in payments or contract slippage could quickly pressure liquidity. Revenue concentration is a real concern, with Nigeria such a large share of 2025 sales that the loss or deferral of a single major project could materially dent the top line.
The company's fortunes remain closely linked to oil-and-gas capital spending, an inherently cyclical driver, and management has itself flagged uncertainty over how Middle East conflict might affect 2026. The PFAS opportunity, while potentially large, depends on a regulatory timetable that has drifted, with US EPA compliance deadlines extended toward 2029, so near-term contribution may be limited. And the shares are Illiquid and have already risen a long way; on trailing figures the rating looks demanding, leaving scope for sharp reversals if execution disappoints.
Investor takeaway
MyCelx (LSE:MYX) has done the hard part of turning a long-loss-making technology into a profitable business, and the market has rewarded that with a dramatic re-rating. The latest small gain looks less like a reaction to any single catalyst and more like ongoing interest in a genuine environmental-technology turnaround. Investors will want to monitor whether the recurring-revenue strategy delivers steadier growth, whether the balance sheet can be strengthened without heavy dilution, and whether contract momentum is sustained. For a company this small, with cash this tight and a valuation that already prices in success, reward and risk remain finely balanced.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...